MSA - Ataxia UK

MSA

Alterity Therapeutics announces positive results from its phase 2 trial of the drug ATH434 in MSA

Cerebellar ataxia, Research News, Uncategorised /

On January 30th 2025, the pharmaceutical company Alterity Therapeutics announced positive data from their phase 2 placebo-controlled trial in early-stage MSA. MSA is a progressive neurological condition leading to impaired […]

Alterity Therapeutics announces positive results from its phase 2 trial of the drug ATH434 in MSA Read More »

Alterity Therapeutics presents data on the potential of ATH434 to treat FA

Cerebellar ataxia, Cerebellar ataxia pharma news, Friedreich's ataxia, Friedreich's ataxia pharma news, Research News /

The biotechnology company Alterity Therapeutics presented data from their lead Friedreich’s ataxia (FA) drug candidate ATH434 at the 2024 US World Orphan Drug Congress.  In FA, a genetic change in

Alterity Therapeutics presents data on the potential of ATH434 to treat FA Read More »

Cart
Checkout - £0.00
  • 0
  • 1
Scroll to Top